RBC Capital analyst, Douglas Miehm, reiterated his Sector Perform rating on shares of Valeant Pharmaceuticals (NYSE: VRX) after Siliq was ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE